The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol
Anna M Arp, George S Bloom, Anelyssa D'Abreu, Amy Fansler, Kimberlee Meegan, Sarah Ratcliffe, Jaideep Kapur, Carol Manning · 2026
Read The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol by Anna M Arp, George S Bloom, Anelyssa D'Abreu, Amy Fansler, Kimberlee Meegan, Sarah Ratcliffe, Jaideep Kapur, Carol Manning (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13191639.txt.
Description
Anna Arp and seven co-authors lay out a pilot trial of memantine to prevent Alzheimer's disease. Their 2026 paper gives the reasons and the protocol for the study. Alzheimer's pathology starts decades before symptoms, so prevention must start early. Memantine, a drug that tempers a brain receptor, is their candidate shield.
The two-year trial is blinded and compares the drug against placebo in equal groups. Volunteers aged fifty to sixty-five carry a risk gene and have a parent or sibling with the disease. Brain scans for amyloid are taken before and after treatment. Thinking tests and health exams recur through the study. The pilot's chief aim is feasibility: how many join and how many finish.
Catalog record
| CREATOR | Anna M Arp, George S Bloom, Anelyssa D'Abreu, Amy Fansler, Kimberlee Meegan, Sarah Ratcliffe, Jaideep Kapur, Carol Manning |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |